Composition of Faron Pharmaceutical’s Shareholders’ Nomination Board
Faron Pharmaceuticals Ltd announced the re-election of three members to its Shareholders' Nomination Board by the company's five largest shareholders. Timo Syrjälä will serve as Chair, representing himself, while Erkka Kohonen and Joonas Haakana will represent Varma Mutual Pension Insurance Company and UMO Capital, respectively. This three-member board is responsible for preparing proposals regarding the composition and remuneration of the Board of Directors for the Annual General Meeting, with the Chair of the Board of Directors attending as an expert.
Select text to share a quote on X · sign in to keep highlights & notes in your FARN notes
| Faron Pharmaceuticals Ltd | Company announcement | December 17, 2025 at 16:30:00 EET |
TURKU, FINLAND - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces that the following members have been re-elected by a meeting of the Company's five largest shareholders to Faron Pharmaceuticals Ltd’s Shareholders' Nomination Board:
Timo Syrjälä, representing himself (Chair)
Erkka Kohonen, representing Varma Mutual Pension Insurance Company, and
Joonas Haakana, representing UMO Capital
Faron’s Shareholders' Nomination Board consists of three members, which represent the Company's shareholders. The Chair of Faron’s Board of Directors, Mr. Tuomo Pätsi, will serve as an expert in the Nomination Board without being a member.
The Shareholders' Nomination Board prepares and presents proposals to the Annual General Meeting on the number, composition and remuneration of the members of the Board as well as the Chair of the Board of Directors.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.